Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 20, 2008. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific transaction notification and does not contain a financial statement or performance summary.
Material Changes
The filing reports a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs for Dr. R G Greig on May 16, 2008, at a price of $44.46 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the specific transaction.
Key Facts for Investor Verification
- Transaction Date: May 16, 2008.
- Individual Involved: Dr. R G Greig.
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Price per ADR: $44.46.
- Regulatory Basis: Notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).